Autopsy report · NCT03686657

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Clinical stage asset and the sponsorship have been acquired by Myopharm Limited.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 1, Phase 2
Sponsor: ARKAY Therapeutics
Sponsor type: Industry
Conditions: Type 2 Diabetes; High Blood Pressure; Arthritis; Obesity
Interventions: Metformin; Val, Cel and Met XR Low; Val, Cel and Met XR High
Participants: 0
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.